LogoThe Incretin Space
Login
Subscribe

GLP-1

Insulin lever to 11

GLP-1

+5

GLP-1 and the kidneys

Dec 16, 2025

•

40 min read

GLP-1 and the kidneys

Incretins are changing the narrative of chronic kidney disease

GLP-1

+3

First Retatrutide phase 3 data, a Triumph of Science!

Dec 11, 2025

•

10 min read

First Retatrutide phase 3 data, a Triumph of Science!

Bariatric surgery in a shot! It might be too effective?! And what's dysesthesia?

GLP-1

Structuring a better mousetrap, aleniglipron

Dec 8, 2025

•

9 min read

Structuring a better mousetrap, aleniglipron

Small molecule, flashy results, is it too late to the party?

GLP-1

+2

Obesity Week 2025 Medications

Nov 14, 2025

•

31 min read

Obesity Week 2025 Medications

Orforglipron, HRS 9531, MET-097, Eloralintide and Mazdutide, OH MY!

GLP-1

+1

GIP: The gentle & sensitive incretin

Sep 5, 2025

•

13 min read

GIP: The gentle & sensitive incretin

Less nausea, more insulin sensitivity, and a little less inflammation Part 2 in a series on GIP

GLP-1

+2

GIP: The unsung incretin

Jul 29, 2025

•

15 min read

GIP: The unsung incretin

The master incretin of the alpha and beta cell starts to shinePart 1 in a series on GIP

GLP-1

+1

ADA Conference 2025: Orforglipron & Bimagrumab

Jun 26, 2025

•

9 min read

ADA Conference 2025: Orforglipron & Bimagrumab

Lilly's oral non-peptide GLP-1 could change everything & bimagrumab flexes its muscle, but at what cost?

GLP-1

+1

ADA Conference 2025: CagriSema

Jun 24, 2025

•

9 min read

ADA Conference 2025: CagriSema

Novo's Dual Amylin-GLP1 agonist shows promise but caveats apply

The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine


Home

© 2026 The Incretin Space.
Report abusePrivacy policyTerms of use
beehiivPowered by beehiiv